The Structural Genomics Consortium (SGC) of Canada has announced a strategic partnership with China-based HitGen Inc. (SHA: 688222). This collaboration will leverage HitGen’s DNA-encoded library (DEL) technology platform to screen under-represented targets identified by SGC. The resulting screening datasets will be made available on a publicly accessible portal, enabling global experts to model the data and predict new active molecules for experimental testing as part of SGC’s ambitious Target 2035 initiative.
HitGen’s OpenDEL Platform: A Game Changer for Affinity Screening
As part of the agreement, HitGen will utilize its OpenDEL platform, a self-service DEL kit that contains over 3 billion compounds. This innovative platform allows users to conduct DEL selection campaigns without disclosing the target identity. Researchers can perform affinity screening experiments against specific protein targets within their own laboratories, significantly enhancing the flexibility and accessibility of drug discovery efforts.
SGC: A Collaborative Force in Drug Discovery
The SGC is a global public-private partnership dedicated to accelerating drug discovery through collaborative efforts among scientists in academia and industry. The consortium is committed to making all research outputs openly available to the scientific community. Current SGC research sites include prestigious institutions such as Goethe University in Frankfurt, Karolinska Institute, McGill University, University College London, the University of North Carolina at Chapel Hill, and the University of Toronto.-Fineline Info & Tech
